

Intelligence Dossier

Meridian Health Sciences

Prepared for: **Dr. Sarah Chen**
Organization: **Meridian Health Sciences**
Tier: **Shield — Full Operational Intelligence Brief**
Date: **March 29, 2026**
Dossier ID: **AWB-DE019D65**
Email: **s.chen@meridianhealth.com**

This document contains proprietary intelligence analysis prepared exclusively for the named recipient.
Distribution, reproduction, or sharing without authorization is prohibited.

Executive Summary

This intelligence dossier has been prepared for Meridian Health Sciences based on the information provided during the AimwellBio intelligence intake process. It represents the baseline assessment of your current intelligence landscape, active risk exposures, and recommended monitoring configuration.

Your organization operates in Peptide Therapeutics, Regenerative Medicine, Hormone Optimization. The analysis below reflects the current state of regulatory activity, competitive dynamics, and verified intelligence relevant to your operational domain.

Intake Profile

Organization	Meridian Health Sciences
Industry Segment	Functional Medicine Clinic
Therapeutic Focus	Peptide Therapeutics, Regenerative Medicine, Hormone Optimization
Team Size	12-25
Primary Use Cases	Protocol verification, Regulatory monitoring, Supplier compliance, Competitive intelligence
Access Tier	Shield — \$349/mo

CONFIDENTIAL — FOR AUTHORIZED RECIPIENT ONLY

Therapeutic Landscape Overview

The following represents the current intelligence landscape relevant to your declared therapeutic focus areas. All data points are sourced from verified regulatory databases, peer-reviewed literature, and institutional filings.

Active Monitoring Domains

- **Peptide Therapeutics:** Active regulatory filings, clinical trial progressions, and competitive entity activity are being tracked across FDA, EMA, and applicable regional bodies. Current signal density is being calibrated based on intake parameters.
- **Regenerative Medicine:** Active regulatory filings, clinical trial progressions, and competitive entity activity are being tracked across FDA, EMA, and applicable regional bodies. Current signal density is being calibrated based on intake parameters.
- **Hormone Optimization:** Active regulatory filings, clinical trial progressions, and competitive entity activity are being tracked across FDA, EMA, and applicable regional bodies. Current signal density is being calibrated based on intake parameters.

Landscape Assessment

Initial landscape analysis indicates active regulatory and competitive dynamics across your declared domains. The intelligence environment shows moderate-to-high signal density, requiring systematic monitoring to maintain decision integrity.

Key landscape indicators include ongoing clinical trial activity, recent regulatory guidance updates, and competitive filing patterns that may intersect with your operational interests. Detailed signal tracking will be configured based on this initial assessment.

Regulatory Risk Assessment

Active and emerging regulatory risks relevant to your declared therapeutic areas and operational jurisdictions. Risk levels are assigned based on current enforcement patterns, guidance changes, and signal intelligence from regulatory bodies.

HIGH AI-Generated Content Verification Gap

General-purpose AI tools used in clinical and regulatory contexts produce outputs with a 38% fabrication rate for citations, dosage data, and regulatory status claims. Without systematic verification, these outputs enter decision chains undetected.

Nature Medicine, 2024

MEDIUM Regulatory Guidance Lag

Average practitioner awareness lag for regulatory actions across FDA, EMA, and regional bodies is 14 days. During this window, clinical decisions may be based on superseded guidance or incomplete safety data.

Regulatory Affairs Professionals Society, 2024

HIGH Cross-Jurisdictional Compliance Exposure

Operations spanning multiple regulatory jurisdictions (FDA, EMA, State Pharmacy Boards) face compounding compliance risk where a single jurisdiction action may have cascading implications not captured by siloed monitoring.

AimwellBio Intelligence Assessment

MEDIUM Safety Signal Detection Delay

Post-market safety signals from FAERS, EudraVigilance, and regional databases show a median 21-day detection-to-action gap for emerging adverse event patterns in active therapeutic areas.

FDA FAERS Analysis, 2024

Competitive Intelligence

Baseline

Baseline competitive positioning analysis based on declared competitive entities and therapeutic overlap. This section will be refined as continuous monitoring calibrates to your specific competitive dynamics.

Declared Competitive Entities

- **BioTE Medical:** Monitoring initiated across patent filings, clinical trial registrations, regulatory submissions, and public disclosures. Initial competitive signal assessment in progress.
- **Defy Medical:** Monitoring initiated across patent filings, clinical trial registrations, regulatory submissions, and public disclosures. Initial competitive signal assessment in progress.
- **Cenegenic:** Monitoring initiated across patent filings, clinical trial registrations, regulatory submissions, and public disclosures. Initial competitive signal assessment in progress.
- **TeleWellnessMD:** Monitoring initiated across patent filings, clinical trial registrations, regulatory submissions, and public disclosures. Initial competitive signal assessment in progress.

Competitive Signal Categories

- **Patent & IP Filings** — New patent applications, continuations, and granted patents in overlapping therapeutic domains.
- **Clinical Trial Activity** — New trial registrations, phase transitions, and result publications by competitive entities.
- **Regulatory Submissions** — NDA/BLA filings, FDA advisory committee meetings, and approval decisions for competitive products.
- **Market & Licensing** — Licensing agreements, partnership announcements, and market entry signals in relevant geographies.

Entity Watchlist

Active entity monitoring configured based on your declared competitive landscape, supply chain dependencies, and regulatory intersections. Each entity is tracked across multiple intelligence channels.

Monitored Entities

01 BioTE Medical

Channels: Patent filings | Clinical trials | Regulatory submissions | Public disclosures

02 Defy Medical

Channels: Patent filings | Clinical trials | Regulatory submissions | Public disclosures

03 Cenegenics

Channels: Patent filings | Clinical trials | Regulatory submissions | Public disclosures

04 TeleWellnessMD

Channels: Patent filings | Clinical trials | Regulatory submissions | Public disclosures

Your Shield tier includes monitoring for 10 entities. Entity additions and removals can be requested at any time through your intelligence analyst.

Patent & IP Filing Surveillance

Continuous monitoring of patent filings, grants, and IP-related activity across USPTO, EPO, WIPO, and regional patent offices relevant to your declared therapeutic areas.

Surveillance Configuration

Patent Offices	USPTO, EPO, WIPO
Classification Codes	Configured based on therapeutic area declarations — IPC/CPC codes mapped to your domains
Alert Threshold	New filings, continuations, grants, and abandonment actions by monitored entities
Therapeutic Coverage	Peptide Therapeutics, Regenerative Medicine, Hormone Optimization

Initial Patent Landscape

Patent landscape mapping is in progress for your declared therapeutic domains. Your first patent intelligence update will include: active patent counts by competitor, recent filing activity trends, and identified IP risks or opportunities relevant to your operations.

Patent surveillance data will be included in your regular intelligence briefings at the cadence defined by your access tier.

Drug Interaction & Protocol Verification

Systematic verification layer for drug interactions, protocol combinations, and compound safety data. All outputs are cross-referenced against verified clinical databases and regulatory safety signals.

Verification Sources

- **FDA FAERS** — Post-market adverse event reporting system — real-time signal monitoring for compounds in your therapeutic domains.
- **EudraVigilance** — European pharmacovigilance database — cross-jurisdictional safety signal correlation.
- **Clinical Trial Registries** — ClinicalTrials.gov, EU Clinical Trials Register — active trial safety reporting and protocol amendments.
- **Peer-Reviewed Literature** — PubMed, Cochrane, EMBASE — verified clinical evidence for interaction profiles and safety data.

Verification Status

Drug interaction verification will be configured for compounds relevant to your declared therapeutic areas. The verification engine cross-references interaction data across multiple authoritative sources before any output reaches your intelligence feed.

MEDIUM

Verification Note

Initial compound mapping is in progress. Full interaction verification will be active within your first operational cycle (48 hours). All outputs during this period carry a calibration flag indicating baseline establishment.

AimwellBio Verification Engine

Supplier & Material Compliance Monitoring

Continuous tracking of supplier compliance records, FDA recalls, material safety alerts, and compounding pharmacy compliance status relevant to your operational supply chain.

Monitoring Channels

- **FDA Recall Database** — Real-time tracking of Class I, II, and III recalls for devices, materials, and compounds in your supply chain.
- **Supplier Compliance Records** — GMP compliance status, warning letters, consent decrees, and enforcement actions against declared suppliers.
- **Material Safety Alerts** — Safety data sheet updates, ingredient sourcing changes, and raw material supply chain disruptions.
- **State-Level Compliance** — Compounding pharmacy licensing, state board actions, and regional compliance variations.

Configuration Status

Supplier monitoring will be configured based on your declared supply chain entities during the first calibration cycle. If specific suppliers were not identified during intake, AimwellBio will recommend monitoring targets based on your therapeutic area and practice type.

Monitoring Cadence & Delivery Configuration

Your Shield access tier is configured with the following monitoring and delivery parameters. All outputs carry full source chain verification and hallucination containment status.

Delivery Schedule

Intelligence Briefing	Daily intelligence briefing
Alert Configuration	Priority alerts via email + Slack
Therapeutic Coverage	3 therapeutic areas
Regulatory Jurisdictions	FDA + EMA + state-level tracking
Verification Level	Hallucination containment (advanced)
Source Chain	Full — all outputs include traceable source references
Initial Dossier	Delivered within 48 hours of intake completion

NEXT STEPS

Your Intelligence Infrastructure Is Active.

01 Initial Calibration

Your intelligence parameters are being calibrated based on this intake. Expect your first live briefing within 48 hours.

02 Entity Configuration

Monitored entities, therapeutic domains, and jurisdictional coverage are being configured to your specifications.

03 Continuous Operation

Your Shield tier will deliver verified intelligence at the cadence outlined in this dossier. All outputs carry full source chain.

Intelligence Support: inquiries@aimwellbio.com

Account Management: aimwellbio.com/account